Relmada Therapeutics Q1 2024 GAAP EPS $(0.72) Beats $(0.84) Estimate
Portfolio Pulse from Benzinga Newsdesk
Relmada Therapeutics reported Q1 2024 GAAP EPS of $(0.72), surpassing the $(0.84) estimate, marking a 17.24% improvement over last year's $(0.87) per share loss.
May 08, 2024 | 9:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relmada Therapeutics reported a smaller than expected quarterly loss of $(0.72) per share, beating estimates and showing improvement over the previous year.
Beating EPS estimates typically leads to positive investor sentiment, potentially driving up the stock price in the short term. The improvement over the previous year's losses further strengthens the case for a positive outlook on RLMD's financial health and operational efficiency.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100